Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Moya Bio is developing a novel class of tumor immune conditioning agents. The company's inhibitors of the FAT10 pathway are designed to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations. Moya Bio's translational data demonstrates a correlation between FAT10 down regulation, increased T-cell infiltration into the tumor microenvironment, and inhibition of tumor growth.
The molecular mechanism underlying Moya's FAT10 inhibition platform supports a synergistic effect with immune checkpoint inhibitors, which is expected to enhance their clinical efficacy.